24/7 Market News- Adial Pharmaceuticals Files New Patent Application for AD04
DENVER, Colo., Jul 31, 2024 (247marketnews.com)- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) stated that it filed a new AD04 patent application`, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) for patients who consume 10, or more, alcoholic drinks per day.
Adial’s CEO and President, Cary Claiborne, stated, “As we continue to advance the AD04 program with the progress of our pharmacokinetics study of AD04, this new patent application and it’s expected approval will extend protection of the core assets of Adial out to at least 2044. This application is the result of an extensive examination of data and information which occurred after Adial hired new patent counsel to bolster and leverage the company’s intellectual property portfolio.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (ADIL)
- Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
- Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
- Today’s Top Performers: MoBot’s Market Review 07/29/25 08:00 AM
- Today’s Top Performers: MoBot’s Market Review 07/28/25 04:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/28/25 11:00 AM